NCT00258388 - Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 28, 2005

Primary Completion Date

November 8, 2007

Study Completion Date

January 18, 2011

Conditions

Prostate Cancer

Interventions

DRUG

custirsen sodium

"640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)~Subsequent cycles:~weekly on days 1, 8, 15 (3 week cycles)"

DRUG

docetaxel

75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)

DRUG

prednisone

5mg PO BID

Trial Locations (13)

University of Washington, Seattle

Tom Baker Cancer Centre, Calgary

Cross Cancer Institute, Edmonton

QEII Health Sciences Center, Halifax

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

BCCA - Cancer Centre for the Southern Interior, Kelowna

London Regional Cancer Program, London

CHUM - Hopital Notre-Dame, Montreal

Atlantic Health Sciences Corporation, Saint John

Odette Cancer Centre, Toronto

Univ. Health Network-Princess Margaret Hospital, Toronto

BCCA - Vancouver Cancer Centre, Vancouver

CancerCare Manitoba, Winnipeg